Skye Bioscience (SKYE) investor relations material

Opening remarks and agenda

• Meeting called to order at 10:00 A.M. Pacific Time on May 26, 2026, with board nominees and independent auditor present.

• Inspector of Election appointed and oath filed; meeting held per notice and proxy statement.

• Proof of mailing of proxy materials and notice to stockholders confirmed.

Shareholder proposals

• Four proposals presented: election of six directors, ratification of auditor, amendment to increase authorized shares, and advisory vote on executive compensation.

Overview of voting outcomes

• Quorum established with 66.98% of shares represented.

• All six director nominees elected for one-year terms expiring at the 2027 meeting.

• Auditor appointment ratified for fiscal year ending December 31, 2026.

• Amendment to increase authorized shares from 100 million to 300 million approved.

• Advisory approval of executive compensation passed.

• Final vote results to be reported in a Form 8-K filing within four business days.